心房顫動抗凝治療中國專家共識doc-資料下載頁
2025-07-18 04:12本頁面
【正文】 sen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ＇real world＇ nationwide cohort study. Thromb Haemost 2011, 106: 739 16. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008, 28: 380 17. Weitz J, Hirsh J. New anticoagulant drugs. Chest 2001, 119(Suppl): 95S 18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361: 1139 19. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011, 171:1285. 20. Jacobs JM and Stessman J. New anticoagulant drugs among elderly patients. Is caution necessary? Arch Intern Med 2011, 171:1287 21. Perzborn E, Strassburger J, Wilmein A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 597939: An oral, direct factor Xa inhibitor. J Thromb Haemost 2005, 3: 514 22. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban— an oral, direct factor Xa inhibitor—in healthy subjects. Int J Clin Pharmacol Therap 2007, 45: 335 23. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 597939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61: 873 24. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 597939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006, 46: 549 25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011,365:883 26. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011,364:806 27. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial Engl J Med 2011,365:981 說明：“高血壓”系指收縮壓160 mm Hg；“腎功能異?！毕抵搁L期透析或腎移植或血清肌酐≥200μmol/L者；“肝功能異常”指慢性肝?。ɡ绺斡不┗蚓哂懈喂δ苊黠@受損的生化證據(jù)（膽紅素高于正常上限的2倍，谷草轉(zhuǎn)氨酶/谷丙轉(zhuǎn)氨酶/堿性磷酸酶高于正常上限的3倍等）；“藥物”是指同時應(yīng)用抗血小板藥物、非甾體類抗炎藥物、皮質(zhì)激素等增強(qiáng)華法林作用的藥物。 中華醫(yī)學(xué)會心血管病學(xué)分會 中華醫(yī)學(xué)會心電生理和起搏分會 中國老年學(xué)學(xué)會心腦血管病專業(yè)委員會 中國生物醫(yī)學(xué)工程學(xué)心律分會 中國醫(yī)師協(xié)會循證醫(yī)學(xué)專業(yè)委員會 心律失常聯(lián)盟（中國）
職業(yè)教育相關(guān)推薦
鄂ICP備17016276號-1